ArticleCancer biology & therapy2026
UBE2S promotes gastric cancer progression through RACGAP1 stabilization associated with K292-dependent K63-linked ubiquitination.
Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGastric cancer (GC) remains highly lethal, and effective molecular targets are limited. This study investigated the expression, exploratory survival associations, and mechanistic role of UBE2S in GC.
methodsUBE2S expression and survival associations were analyzed using public datasets, whereas UBE2S protein expression was assessed in seven paired GC tissues and GC cell lines. Loss- and gain-of-function assays, xenograft models, quantitative proteomics, genetic rescue, JNK inhibition, co-immunoprecipitation, cycloheximide chase, proteasome inhibition, and linkage-specific ubiquitination assays were performed.
resultsUBE2S was upregulated in GC and showed apparent within-dataset discriminatory ability at the tissue-transcript level (AUC = 0.909); higher expression showed an exploratory association with unfavorable survival in public datasets. Protein assessment in seven paired tissues was consistent with this expression pattern. UBE2S depletion suppressed GC cell viability, clonogenicity, migration, and xenograft growth. Proteomics prioritized RACGAP1 as a candidate downstream effector, and subsequent rescue experiments supported its functional relevance. UBE2S associated with RACGAP1 and increased RACGAP1 protein stability without altering its mRNA expression. UBE2S depletion decreased K63-linked and increased K48-linked ubiquitination of RACGAP1, whereas MG132 partially restored RACGAP1 abundance. K292 mutation impaired UBE2S-dependent K63-linked ubiquitination, RACGAP1 accumulation, JNK/c-Jun activation, and malignant phenotypes, although RACGAP1-K292R retained partial activity. Pharmacological JNK inhibition with SP600125 suppressed RACGAP1-mediated JNK/c-Jun reactivation and clonogenic rescue.
conclusionOur findings support a model in which UBE2S promotes GC progression by stabilizing RACGAP1 in association with K292-dependent K63-linked ubiquitination, providing a mechanistic basis for further preclinical investigation of the UBE2S/RACGAP1/JNK/c-Jun axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.